|
Market Closed -
Nasdaq
21:00:00 03/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 34.41 USD | +0.57% |
|
+0.91% | +11.72% |
| 09-03 | Handelsbanken Adds Xvivo and Vimian as Sector Favorites, Drops Danish Duo | FW |
| 09-01 | Deutsche Bank raises price target for Genmab to 2,500 Danish kroner, reiterates buy | FW |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| GENMAB A/S | Bio Therapeutic Drugs | +0.57% | +0.91% | +11.72% | +27.07% | -29.37% | 20.4B |
-
|
-
|
-
|
- Stock Market
- Stocks
- GMAB Stock
- GMAB Stock
- Charts Genmab A/S
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
